In melanoma, tumor-associated B cells are essential to sustain adequate T cell activation and trigger the inflammatory response with anti-PD-1 blockade, both in mice and in humans, with the number of peripheral-blood memory B cells detected during pretherapy being predictive of response and overall survival to ICI treatment (11, 12). The gene discussed is PDCD1; the disease is melanoma.